| 1 | Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ) JCO Precis Oncol 2024 Apr;8:e2300567 13 Citations |
| 1 | Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. (Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA) J Immunother Cancer 2023 Jun;11(6) 45 Citations |
| 1 | Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology. (Earland N, Chen K, Semenkovich NP, Chauhan PS, Zevallos JP, Chaudhuri AA) Semin Radiat Oncol 2023 Jul;33(3):262-278 12 Citations |
| 1 | Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. (Rosenberg S, Ben Cohen G, Kato S, Okamura R, Lippman SM, Kurzrock R) Mol Oncol 2023 Sep;17(9):1844-1856 3 Citations |
| 1 | Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. (De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G) Cancer Discov 2023 Mar 01;13(3):632-653 44 Citations |
| 1 | Liquid biopsy: current technology and clinical applications. (Nikanjam M, Kato S, Kurzrock R) J Hematol Oncol 2022 Sep 12;15(1):131 571 Citations |
| 1 | Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA. (Pacia CP, Yuan J, Yue Y, Xu L, Nazeri A, Desai R, Gach HM, Wang X, Talcott MR, Chaudhuri AA, Dunn GP, Leuthardt EC, Chen H) Theranostics 2022;12(1):362-378 45 Citations |
| 1 | STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. (Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R) Eur J Cancer 2021 May;148:215-229 38 Citations |
| 1 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. (Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R) Nat Commun 2020 Oct 02;11(1):4965 224 Citations |
| 1 | Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. (Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R) Mol Cancer Ther 2020 Dec;19(12):2612-2620 10 Citations |
| 1 | Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. (Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R) Mol Oncol 2021 Jan;15(1):67-79 40 Citations |
| 1 | Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. (Baumgartner JM, Riviere P, Lanman RB, Kelly KJ, Veerapong J, Lowy AM, Kurzrock R) Ann Surg Oncol 2020 Sep;27(9):3259-3267 23 Citations |
| 1 | Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. (Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK) Int J Cancer 2021 Feb 01;148(3):702-712 59 Citations |
| 1 | Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. (Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW) Breast Cancer Res Treat 2020 Aug;182(3):665-677 1 Citation |
| 1 | ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. (Baumgartner JM, Riviere P, Kurzrock R) Ann Surg Oncol 2020 Sep;27(9):3268-3269 |
| 1 | Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. (Bieg-Bourne CC, Okamura R, Kurzrock R) Mol Oncol 2020 Jun;14(6):1242-1251 17 Citations |
| 2 | Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. (Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME) J Clin Oncol 2020 Apr 20;38(12):1273-1283 370 Citations |
| 1 | Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. (Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R) J Hematol Oncol 2019 Dec 04;12(1):130 81 Citations |
| 1 | Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. (Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R) Clin Cancer Res 2019 Oct 15;25(20):6107-6118 67 Citations |
| 1 | Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. (Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R) Mol Cancer Ther 2019 Oct;18(10):1852-1862 20 Citations |
| 1 | Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. (Mardinian K, Okamura R, Kato S, Kurzrock R) Int J Cancer 2020 Jan 15;146(2):566-576 20 Citations |
| 1 | Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. (Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R) Mol Cancer Ther 2019 May;18(5):1001-1011 38 Citations |
| 1 | Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. (Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC) Prostate 2019 May;79(7):701-708 24 Citations |
| 1 | ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis. (Baumgartner JM, Kurzrock R) Ann Surg Oncol 2018 Dec;25(Suppl 3):772-773 |
| 1 | Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. (Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R) Clin Cancer Res 2018 Dec 15;24(24):6248-6256 106 Citations |
| 2 | Novel biomarkers in multiple myeloma. (Levin A, Hari P, Dhakal B) Transl Res 2018 Nov;201:49-59 36 Citations |
| 1 | Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. (Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R) Ann Surg Oncol 2018 Aug;25(8):2400-2408 58 Citations |
| 1 | MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. (Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R) J Hematol Oncol 2018 Jun 04;11(1):76 37 Citations |
| 1 | Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. (Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L) Prostate Cancer Prostatic Dis 2018 Sep;21(3):411-418 35 Citations |
| 1 | Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. (Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R) Oncologist 2018 May;23(5):586-593 77 Citations |
| 1 | Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. (Ikeda S, Lim JS, Kurzrock R) Mol Cancer Ther 2018 May;17(5):1114-1122 54 Citations |
| 1 | Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. (Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA) Clin Cancer Res 2018 Apr 15;24(8):1881-1890 60 Citations |
| 1 | The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. (Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R) Mol Cancer Ther 2018 Jan;17(1):297-305 34 Citations |
| 1 | Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. (Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R) Clin Cancer Res 2017 Oct 01;23(19):5729-5736 181 Citations |
| 1 | Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. (Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R) Oncologist 2017 Jun;22(6):631-637 98 Citations |
| 1 | Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. (Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R) Clin Cancer Res 2017 Sep 01;23(17):5101-5111 132 Citations |
| 1 | Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. (Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R) Clin Cancer Res 2017 Aug 15;23(16):4716-4723 115 Citations |
| 1 | Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. (Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF) Clin Cancer Res 2017 Jan 15;23(2):536-548 28 Citations |
| 1 | Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. (Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R) Clin Cancer Res 2016 Nov 15;22(22):5497-5505 119 Citations |
